Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Biomaterials ; 77: 267-79, 2016 Jan.
Article de Anglais | MEDLINE | ID: mdl-26610076

RÉSUMÉ

The development of novel non-viral delivery vehicles is essential in the search of more efficient strategies for retina and brain diseases. Herein, optimized niosome formulations prepared by oil-in water (o/w) and film-hydration techniques were characterized in terms of size, PDI, zeta potential, morphology and stability. Three ionizable glycerol-based cationic lipids containing a primary amine group (lipid 1), a triglycine group (lipid 2) and a dimethylamino ethyl pendent group (lipid 3) as polar head-groups were part of such niosomes. Upon the addition of pCMS-EGFP plasmid, nioplexes were obtained at different cationic lipid/DNA ratios (w/w). The resultant nioplexes were further physicochemically characterized and evaluated to condense, release and protect the DNA against enzymatic digestion. In vitro experiments were performed to evaluate transfection efficiency and cell viability in HEK-293, ARPE-19 and PECC cells. Interestingly, niosome formulations based on lipid 3 showed better transfection efficiencies in ARPE-19 and PECC cells than the rest of cationic lipids showed in this study. In vivo experiments in rat retina after intravitreal and subretinal injections together with in rat brain after cerebral cortex administration showed promising transfection efficiencies when niosome formulations based on lipid 3 were used. These results provide new insights for the development of non-viral vectors based on cationic lipids and their applications for efficient delivery of genetic material to the retina and brain.


Sujet(s)
Cortex cérébral/métabolisme , Vecteurs génétiques/composition chimique , Liposomes/composition chimique , Propanolamines/pharmacologie , Rétine/métabolisme , Transfection/méthodes , Urée/analogues et dérivés , Animaux , Cations , Lignée cellulaire , Cellules cultivées , ADN/administration et posologie , ADN/génétique , Stabilité de médicament , Gènes rapporteurs , Vecteurs génétiques/administration et posologie , Protéines à fluorescence verte/biosynthèse , Protéines à fluorescence verte/génétique , Cellules HEK293 , Hippocampe/cytologie , Hippocampe/embryologie , Humains , Interactions hydrophobes et hydrophiles , Injections oculaires , Injections intravitréennes , Liposomes/administration et posologie , Mâle , Neurones/cytologie , Propanolamines/administration et posologie , Propanolamines/synthèse chimique , Rats , Rat Sprague-Dawley , Épithélium pigmentaire de la rétine/cytologie , Urée/administration et posologie , Urée/synthèse chimique , Urée/pharmacologie
2.
Mol Pharm ; 12(10): 3658-71, 2015 Oct 05.
Article de Anglais | MEDLINE | ID: mdl-26334586

RÉSUMÉ

The present study aimed to evaluate the incorporation of protamine into niosome/DNA vectors to analyze the potential application of this novel ternary formulation to deliver the pCMS-EGFP plasmid into the rat retina. Binary vectors based on niosome/DNA and ternary vectors based on protamine/DNA/niosomes were prepared and physicochemically characterized. In vitro experiments were performed in ARPE-19 cells. At 1:1:5 protamine/DNA/niosome mass ratio, the resulted ternary vectors had 150 nm size, positive charge, spherical morphology, and condensed, released, and protected the DNA against enzymatic digestion. The presence of protamine in the ternary vectors improved transfection efficiency, cell viability, and DNA condensation. After ocular administration, the EGFP expression was detected in different cell layers of the retina depending on the administration route without any sign of toxicity associated with the formulations. While subretinal administration transfected mainly photoreceptors and retinal pigment epithelial cells at the site of injection, intravitreal administration produced a more uniform distribution of the protein expression through the inner layers of the retina. The protein expression in the retina persisted for at least one month after both administrations. Our study highlights the flattering properties of protamine/DNA/niosome ternary vectors for efficient and safe gene delivery to the rat retina.


Sujet(s)
ADN/métabolisme , Techniques de transfert de gènes , Liposomes/usage thérapeutique , Protamine/métabolisme , Rétine/métabolisme , Animaux , Lignée cellulaire , ADN/composition chimique , Technique d'immunofluorescence indirecte , Techniques in vitro , Liposomes/pharmacologie , Mâle , Microscopie de fluorescence , Plasmides/métabolisme , Protamine/composition chimique , Rats , Rat Sprague-Dawley , Rétine/cytologie , Tomographie par cohérence optique , Transfection/méthodes
3.
Org Biomol Chem ; 13(4): 1068-81, 2015 Jan 28.
Article de Anglais | MEDLINE | ID: mdl-25412820

RÉSUMÉ

We designed niosomes based on three lipids that differed only in the polar-head group to analyze their influence on the transfection efficiency. These lipids were characterized by small-angle X-ray scattering before being incorporated into the niosomes which were characterized in terms of pKa, size, zeta potential, morphology and physical stability. Nioplexes were obtained upon the addition of a plasmid. Different ratios (w/w) were selected to analyze the influence of this parameter on size, charge and the ability to condense, release and protect the DNA. In vitro transfection experiments were performed in HEK-293, ARPE-19 and MSC-D1 cells. Our results show that the chemical composition of the cationic head-group clearly affects the physicochemical parameters of the niosomes and especially the transfection efficiency. Only niosomes based on cationic lipids with a dimethyl amino head group (lipid 3) showed a transfection capacity when compared with their counterparts amino (lipid 1) and tripeptide head-groups (lipid 2). Regarding cell viability, we clearly observed that nioplexes based on the cationic lipid 3 had a more deleterious effect than their counterparts, especially in ARPE-19 cells at 20/1 and 30/1 ratios. Similar studies could be extended to other series of cationic lipids in order to progress in the research on safe and efficient non-viral vectors for gene delivery purposes.


Sujet(s)
Lipides/composition chimique , Transfection , Survie cellulaire/effets des médicaments et des substances chimiques , ADN/administration et posologie , ADN/composition chimique , ADN/génétique , Stabilité de médicament , Cellules HEK293 , Humains , Lipides/synthèse chimique , Lipides/toxicité , Liposomes , Taille de particule
4.
J Control Release ; 174: 27-36, 2014 Jan 28.
Article de Anglais | MEDLINE | ID: mdl-24231407

RÉSUMÉ

Niosomes represent a recent promising approach for gene delivery purposes. We elaborated on a novel niosome formulation based on the 2,3-di(tetradecyloxy)propan-1-amine cationic lipid, combined with squalene and polysorbate 80 to evaluate the transfection efficiency in rat retinas. Niosomes prepared by the solvent emulsification-evaporation technique were mixed with the pCMSEGFP plasmid to form lipoplexes which were characterized in terms of morphology, size, surface charge, and DNA condensation, protection and release. In vitro studies were conducted to evaluate transfection efficiency, viability and internalization mechanism in HEK-293 and ARPE-19 cells. The efficacy of the most promising formulation was evaluated in rat eyes by monitoring the expression of the EGFP after intravitreal and subretinal injections. Lipoplexes at 15/1 ratio were 200nm in size, 25mV in zeta potential and exhibited spherical morphology. At this ratio, niosomes condensed and protected the DNA from enzymatic digestion. Lipoplexes successfully transfected HEK-293 and specially ARPE-19 cells, without affecting the viability. Whereas lipoplexes entered mainly retinal cells by clathrin-mediated endocytosis, HEK-293 cells showed a higher caveolae-dependent entry. After ocular administration, the expression of EGFP was detected in different cells of the retina depending on the administration route. This novel niosome formulation represents a promising approach to deliver genetic material into the retina to treat inherited retinal diseases.


Sujet(s)
ADN/administration et posologie , Techniques de transfert de gènes , Éthers de glycéryle/composition chimique , Propylamines/composition chimique , Rétine/métabolisme , Animaux , Lignée cellulaire , ADN/composition chimique , Protéines à fluorescence verte/génétique , Protéines à fluorescence verte/métabolisme , Cellules HEK293 , Humains , Liposomes , Mâle , Rats , Rat Sprague-Dawley
5.
Eur J Pharm Biopharm ; 83(2): 131-40, 2013 Feb.
Article de Anglais | MEDLINE | ID: mdl-23059418

RÉSUMÉ

Ultrapure oligochitosans have recently been evaluated as a promising tool for corneal gene therapy; however, there are no reports regarding the potential use of this polymer in other ocular tissues. We have prepared and characterized at pH 7.1 oligochitosan/pCMS-EGFP polyplexes to evaluate the transfection efficiency in rat retinas after subretinal and intravitreal administration. Polyplexes were characterized in terms of shape, size, surface charge, DNA condensation, and transfection efficiency in HEK-293 and ARPE-19 culture cells. Polyplexes were positively charged, around 10 mV, and size oscillated between 256.5 ± 56 and 67.3 ± 0.44 nm, depending on the nitrogenous/phosphate ratio. Polyplexes efficiently protected the plasmid against enzymatic digestion. A drastic increase in transfection efficiency was observed when pH slightly decreased from 7.4 to 7.1 in both HEK-293 (from 19.1% to 51.5%) and ARPE-19 (from 2.0% to 36.5%) cells (data normalized to Lipofectamine™ 2000). In rat retinas, subretinal administrations transfected cells mainly in the RPE layer, whereas intravitreal injections transfected cells in the inner nuclear and plexiform layers of the retina and mainly in the ganglion cell layer. This study establishes the base for future treatments of genetic retinal disorders with low molecular weight oligochitosan polyplexes.


Sujet(s)
Chitine/analogues et dérivés , ADN/administration et posologie , Rétine/métabolisme , Animaux , Lignée cellulaire , Chitine/administration et posologie , Chitosane , Techniques de transfert de gènes , Thérapie génétique/méthodes , Cellules HEK293 , Humains , Mâle , Masse moléculaire , Oligosaccharides , Taille de particule , Polymères/métabolisme , Rats , Rat Sprague-Dawley , Transfection/méthodes
6.
Eur J Pharm Sci ; 48(1-2): 323-31, 2013 Jan 23.
Article de Anglais | MEDLINE | ID: mdl-23201002

RÉSUMÉ

Non-viral gene therapy represents a promising approach for the treatment of retinal diseases. However, the lack of an efficient carrier hampers the implementation of this therapy. In this study, we evaluated low molecular weight ultrapure oligochitosans for the delivery of the pCMS-EGFP plasmid into the rat retina cells after subretinal and intravitreal administrations. Polyplexes were technologically characterized. Resulting polyplexes based on ultrapure oligochitosans were slightly spherical, protected the plasmid against enzymatic digestion, and their charge and size values ranged from 8 to 14 millivolts and from 150 to 69 nm respectively depending on the N/P ratio. In HEK-293 cultured cells, transfection efficiency significantly increased from 12% to 30% when pH decreased from 7.4 to 7.1 (data normalized to Lipofectamine™ 2000). However, no significant transfection was detected in ARPE-19 cultured cells. Subretinal administrations transfected mainly the pigmented cells of the retinal pigment epithelium and the light sensitive photoreceptor cells, whereas intravitreal injections transfected cells in the ganglion cell layer, blood vessels in the inner layers of the retina and photoreceptors. These results support the potential use of oligochitosans for delivering genetic material into retinal cells in vivo.


Sujet(s)
Chitine/analogues et dérivés , ADN/administration et posologie , Protéines à fluorescence verte/génétique , Rétine/métabolisme , Animaux , Lignée cellulaire , Chitine/administration et posologie , Chitine/composition chimique , Chitosane , ADN/composition chimique , Thérapie génétique/méthodes , Vecteurs génétiques , Protéines à fluorescence verte/composition chimique , Cellules HEK293 , Humains , Mâle , Oligosaccharides , Plasmides , Rats , Rat Sprague-Dawley
7.
Eur J Pharm Sci ; 44(3): 200-6, 2011 Oct 09.
Article de Anglais | MEDLINE | ID: mdl-21820509

RÉSUMÉ

The aim of the present work was to develop an easy, safe and effective vaccine in Balb/c mice using the Aß(1-15) peptide as immunogen entrapped in PLGA microparticles to reduce the risk of an adverse T cell-mediated response. Aß(1-15,) which contains the N-terminal antibody epitope of the full Aß(1-42) peptide was encapsulated in PLGA by a modified solvent evaporation/extraction technique using a double emulsion system. Microparticles were characterized in terms of size distribution (1.22±0.28 µm), encapsulation efficiency (75.05±4.17%), surface associated peptide (59.81±0.96%) and "in vitro" release profile. Balb/c mice were immunized by subcutaneous and intranasal routes with three 30 µg doses of the peptide microencapsulated in PLGA. A solution of the peptide alone and an emulsion in the Freund's adjuvant were administered subcutaneously as control groups. Antibody levels elicited against the toxic Aß(1-40) fraction in the serum of PLGA microparticles treated groups were higher than that of the peptide alone groups. Our initial results indicate that immunotherapy with Aß(1-15) loaded PLGA microparticles could be a promising approach for the future development of a safe vaccine against Alzheimer's disease.


Sujet(s)
Maladie d'Alzheimer/thérapie , Vaccins contre la maladie d'Alzheimer/immunologie , Peptides bêta-amyloïdes/immunologie , Vecteurs de médicaments/composition chimique , Immunoglobuline G/sang , Acide lactique/composition chimique , Fragments peptidiques/immunologie , Acide polyglycolique/composition chimique , Administration par voie nasale , Maladie d'Alzheimer/immunologie , Vaccins contre la maladie d'Alzheimer/administration et posologie , Vaccins contre la maladie d'Alzheimer/usage thérapeutique , Peptides bêta-amyloïdes/administration et posologie , Peptides bêta-amyloïdes/usage thérapeutique , Animaux , Calendrier d'administration des médicaments , Préparation de médicament , Test ELISA , Déterminants antigéniques des lymphocytes B/immunologie , Déterminants antigéniques des lymphocytes T/immunologie , Injections sous-cutanées , Souris , Souris de lignée BALB C , Microscopie électronique à balayage , Taille de particule , Fragments peptidiques/administration et posologie , Fragments peptidiques/usage thérapeutique , Copolymère d'acide poly(lactique-co-glycolique) , Propriétés de surface
8.
J Ocul Pharmacol Ther ; 15(1): 19-27, 1999 Feb.
Article de Anglais | MEDLINE | ID: mdl-10048344

RÉSUMÉ

Aqueous humor dynamics were studied in alpha-chymotrypsin-induced ocular hypertensive rabbits either by tonographic or two-level constant pressure perfusion techniques. A significant correlation was obtained between the values of outflow facility in alpha-chymotrypsin-induced ocular hypertensive rabbits as determined by tonography and constant pressure perfusion. The mean value of tonographic outflow facility in ocular hypertensive rabbits was not statistically different from that found in ocular normotensive rabbits. On the contrary, the estimated rate of aqueous inflow in ocular hypertensive rabbits was about 1.5-fold higher than that of ocular normotensive ones. While topical timolol lowered intraocular pressure and aqueous humor inflow in ocular hypertensive rabbits, pilocarpine did not produce any significant effect. Aqueous humor protein was significantly increased in ocular hypertensive eyes. The results of this study show that accurate measurements of outflow facility can be obtained in alpha-chymotrypsin-induced ocular hypertensive rabbits by tonographic technique. Our data suggest that the long-term ocular hypertension induced by alpha-chymotrypsin in albino rabbits may be secondary to an increase in the rate of aqueous humor inflow, likely produced by a breakdown of the blood-aqueous barrier. This finding strongly conflicts with the hypothesis of trabecular blockage as the cause of alpha-chymotrypsin-induced ocular hypertension in this species.


Sujet(s)
Humeur aqueuse/métabolisme , Hypertension oculaire/métabolisme , Animaux , Chymotrypsine , Protéines de l'oeil/métabolisme , Pression intraoculaire/effets des médicaments et des substances chimiques , Hypertension oculaire/induit chimiquement , Hypertension oculaire/traitement médicamenteux , Pilocarpine/pharmacologie , Lapins , Timolol/pharmacologie , Tonométrie oculaire , Réseau trabéculaire de la sclère/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE